secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2026-05-12T20:04:46+00:00
Accession:  0001140361-26-020805
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q1 net sales $2.4M (+26% YoY); gross margin 70.1%; net loss $4.3M
--------------------------------------------------------------------------

- Net sales $2.4M, up 26% from $1.9M YoY; gross margin 70.1% (improved 14% YoY).
- Net loss $4.3M; operating expenses $6.0M (up from $4.1M) due to sales headcount.
- Cash $2.2M, no debt as of March 31, 2026.
- Acquired Rendiatech (kidney-function monitoring); appointed Carisa Schultz as CFO.
- Appointed Martin J. Emerson and David A. McDonald to Board; new patents and TX territory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036126020805/0001140361-26-020805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036126020805/ef20073181_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer